BRIEF—Selvita names MorphoSys exec as chief medical officer

Poland’s leading biopharma company Selvita today announced the appointment of Steffen Heeger to the role of chief medical officer.

Dr Heeger will join Selvita in February and will be responsible for all clinical, medical affairs and regulatory functions for Selvita oncology pipeline including SEL24, the first-in-class dual PIM/FLT3 kinase inhibitor currently in Phase I/II studies in acute myeloid leukemia, SEL120, the first-in-class selective CDK8 kinase inhibitor, targeting hematological malignancies and solid tumors, currently in IND-enabling studies as well as new programs emerging from three Selvita’s discovery platforms – targeted therapeutics, cancer metabolism and immunometabolism, and immune-oncology.

Dr Heeger is an oncologist with a thorough experience in oncology drug development. Prior to joining Selvita, he held a position of vice president, head of clinical development and head of clinical operations at German biotech MorphoSys, where he focused on the development and execution of clinical strategy for MorphoSys’ lead hematology and oncology products.

Dr Heeger’s previous experience includes also a nine-year tenure at Merck Serono, where he was head of medical affairs.